Dafinchi
Guardant Health Q1 2026 Revenue Insight: No Guidance Change Reported
Guardant Health reported a strong Q1 2026 revenue of $302 million, reflecting a 48% increase year-over-year, with no adjustment to guidance explicitly announced.
Read post
Detailed company information
Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Last Updated: Sep 2026
Earnings Transcript for 2026 - Q2Released: Jul 30, 2026
Earnings Transcript for 2026 - Q1Released: May 07, 2026
Earnings Transcript for 2025 - Q4Released: Feb 19, 2026
Earnings Transcript for 2025 - Q3Released: Oct 30, 2025
Earnings Transcript for 2025 - Q2Released: Jul 31, 2025
Earnings Transcript for 2025 - Q1Released: Apr 30, 2025
Earnings Transcript for 2024 - Q4Released: Feb 20, 2025
Earnings Transcript for 2024 - Q3Released: Nov 06, 2024
Earnings Transcript for 2024 - Q2Released: Aug 07, 2024
Earnings Transcript for 2024 - Q1Released: May 08, 2024
Earnings Transcript for 2023 - Q4Released: Feb 22, 2024
Earnings Transcript for 2023 - Q3Released: Nov 06, 2023
Earnings Transcript for 2023 - Q2Released: Aug 03, 2023
Earnings Transcript for 2023 - Q1Released: May 09, 2023
Earnings Transcript for 2022 - Q4Released: Feb 23, 2023
Earnings Transcript for 2022 - Q3Released: Nov 03, 2022
Earnings Transcript for 2022 - Q2Released: Aug 04, 2022
Earnings Transcript for 2022 - Q1Released: May 05, 2022
Earnings Transcript for 2021 - Q4Released: Feb 23, 2022
Earnings Transcript for 2021 - Q3Released: Nov 04, 2021
Earnings Transcript for 2021 - Q2Released: Aug 06, 2021
Earnings Transcript for 2021 - Q1Released: May 06, 2021
Earnings Transcript for 2020 - Q4Released: Feb 25, 2021
Earnings Transcript for 2020 - Q3Released: Nov 04, 2020
CSTL Castle Biosciences, Inc.
Guardant Health reported a strong Q1 2026 revenue of $302 million, reflecting a 48% increase year-over-year, with no adjustment to guidance explicitly announced.
Read post